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 2 
Abstract 23 
Haploinsufficiency of factors governing genome stability underlies hereditary breast and 24 
ovarian cancer. Homologous recombination (HR) repair is a major pathway disabled in these 25 
cancers. With the aim of identifying new candidate genes, we examined early-onset breast 26 
cancer patients negative for BRCA1 and BRCA2 pathogenic variants. Here, we focused on 27 
CtIP (RBBP8 gene) that mediates HR repair through the end-resection of DNA double-strand 28 
breaks (DSB). Notably, the patients exhibited a number of rare germline RBBP8 variants, and 29 
functional analysis revealed that these variants did not affect DNA DSB end-resection 30 
efficiency. However, expression of a subset of variants led to deleterious nucleolytic 31 
degradation of stalled DNA replication forks in a manner similar to cells lacking BRCA1 or 32 
BRCA2. In contrast to BRCA1 and BRCA2, CtIP deficiency promoted the helicase-driven 33 
destabilization of RAD51 nucleofilaments at damaged DNA replication forks. Taken together, 34 
our work identifies CtIP as a critical regulator of DNA replication fork integrity, which when 35 
compromised, may predispose to the development of early-onset breast cancer. 36 
 3 
  Introduction 37 
Hereditary breast and ovarian cancer (HBOC) is causally linked with 38 
germline pathogenic variants in proteins implicated in homologous 39 
recombination repair (HRR), the protection of stalled DNA replication forks and 40 
cell cycle checkpoint control (1-6). BRCA1 and BRCA2 are the most commonly 41 
mutated genes in HBOC, accounting for approximately 15% of cases (7). 42 
However, a number of less frequent genetic alterations that predispose to 43 
breast cancer have been uncovered in other genes e.g. RECQL1, PALB2 and 44 
BRIP1 (3, 8-10). For the majority of emerging HBOC genes, it is currently not 45 
possible to provide accurate risk estimates because they are rare. This poses 46 
challenges to cancer risk management and counseling of women who carry 47 
variants in these genes as well as burdens their families. Consequently, it has 48 
been proposed that functional analyses should be employed in the 49 
classification of novel genetic variants (1).  50 
Notably, genetic and functional analysis of breast cancer associated 51 
variants have uncovered substantial locus heterogeneity. Several HRR factors, 52 
other than BRCA1 and BRCA2, increase the risk of breast cancer including 53 
PALB2 and RAD51C (1, 8, 11). CtIP, encoded by the RBBP8 gene, is a major 54 
HRR factor that has thus far not been functionally linked with HBOC. CtIP is a 55 
key regulator of double-strand break (DSB) resection operating within the 56 
BRCA1/BRCA2 pathway, and generates the single-stranded DNA segment 57 
needed for RAD51-mediated recombination. Here, we examined a high-risk 58 
population of early-onset BRCA1 and BRCA2 mutation-negative breast cancer 59 
patients for germline variants in RBBP8. Compared to a Danish control cohort, 60 
these patients were enriched for a subset of rare RBBP8 variants. Functional 61 
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analysis revealed that whilst these CtIP variants did not affect DSB resection 62 
efficiency, their expression led to deleterious nucleolytic degradation of stalled 63 
replication forks in a manner similar to cells lacking BRCA1/BRCA2. Notably, 64 
CtIP deficiency promoted the helicase-driven destabilization of RAD51 65 
nucleofilaments at damaged replication forks. Taken together, our work 66 
identifies CtIP as a critical regulator of replication fork integrity that when 67 
mutated may predispose to the development of early-onset breast cancer. 68 
  69 
 5 
Results  70 
Identification of RBBP8 germline variants. We screened a group of 129 71 
Danish high-risk BRCA1 and BRCA2 pathogenic variant-negative breast 72 
cancer patients for germline variants in RBBP8 encoding CtIP (Patient group I, 73 
outlined in Supplementary Figure 1). Fifty percent of women had a 1st or 2nd 74 
degree relative with breast or ovarian cancer and included women below 35 75 
years of age at the time of diagnosis, male breast cancer patients and six 76 
women with early-onset ovarian cancer (Supplementary Table 1). This initial 77 
screening identified five different non-synonymous, heterozygous RBBP8 78 
variants (Table 1 and Figure 1A-B). Three patients were carriers of an in-frame 79 
3-bp deletion in exon 18 (c.2410_2412del; p.E804del), which was detected at 80 
an allele frequency of 1.16%. The p.E804del variant is significantly 81 
overrepresented in our cohort with respect to 2,000 Danes (12). In addition, two 82 
patients were carriers of different missense RBBP8 variants (c.693T>A, 83 
p.S231R in exon 9 and c.1928A>C, p.Q643P in exon 13, respectively), and one 84 
patient carried two different missense variants, (c.298C>T, p.R100W in exon 6 85 
and c.2131G>A, p.E711K in exon 15). Only the p.R100W variant was detected 86 
in 2,000 Danes, whilst the p.Q643P and the p.E711K variant had not been 87 
reported previously (12). 88 
We subsequently sequenced RBBP8 in a larger series of 1,092 patients 89 
negative for BRCA1 and BRCA2 pathogenic variants with breast cancer and/or 90 
ovarian cancer or other related cancer types, as well as unaffected individuals 91 
of families with HBOC (Patient group II, outlined in Supplementary Figure 1). 92 
Nine different heterozygous missense variants in RBBP8 (Table 1 and Figure 93 
1A-B) were identified in 14 females from this cohort. Three patients carried a 94 
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p.R110Q variant, two a p.H456R variant, and three carried the p.Q643P variant 95 
previously identified among patient group I. A further six variants, p.R502L, 96 
p.T675I, p.R805G, p.R839Q, p.P874A and p.E894D, were identified in 97 
individual patients. In total, we identified 13 RBBP8 variants in 21 patients 98 
(Table 1), nine of which were observed once. Finally, we explored an 99 
international cohort of 1054 breast cancer patients without pathogenic variants 100 
in BRCA1 or BRCA2 for rare variants in RBBP8. Here, we identified 17 different 101 
rare variants in 22 patients of which the clinically annotated (n=7) had a median 102 
age of 38 at the time of diagnosis (Supplementary Table 2). These RBBP8-103 
variants also included the p.Q643P variant and two loss-of-function variants 104 
(Supplementary Table 2).  105 
 106 
RBBP8/CtIP variants display a genome maintenance defect. Since our 107 
genetic screening indicated that RBBP8 variants could be associated with 108 
early-onset breast cancer, we investigated whether they affect known CtIP 109 
function(s). Hence, we examined DNA DSB end resection as well as genome 110 
stability after exposure to irradiation (IR) or replication stress induced with 111 
aphidicolin (APH) or hydroxyurea (HU). To create an isogenic system for our 112 
assays, we first depleted endogenous RBBP8/CtIP from breast cancer MCF7 113 
cells with siRNA, and complemented cells with re-expression oif siRNA-114 
resistant CtIP variants (Figure 2A-B). All variants were well expressed; 115 
surprisingly, however, none of these variants affected the ability of cells to 116 
perform DNA DSB end resection after irradiation (Figure 2C; Supplementary 117 
Figure 2A). The phosphorylation of RPA32 on the S4/S8 residues was used as 118 
a readout for the proficiency of DNA DSB end resection after IR in these assays 119 
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(13). Next, we monitored genome stability after exposure to IR, APH or HU, 120 
using the accumulation of extranuclear micronuclei as a readout 121 
(Supplementary Figure 2B). In a manner similar to Wt-CtIP, and in keeping with 122 
our findings above, all the tested variants were able to complement the IR-123 
induced genome instability caused by the loss of CtIP (Table 2). Together, 124 
these data indicate that the identified germline RBBP8 variants do not give rise 125 
to a detectable impairment of DNA DSB repair. However, expression of several 126 
variants (Q643P, E804del, and R805G) as well as the C-terminal truncated 127 
CtIP (ΔC) mutant, failed to complement the genome instability induced by APH 128 
and HU following depletion of endogenous CtIP (Table 2). This suggests that 129 
these variants perturb a function of CtIP specifically associated with the 130 
replication stress response. In addition to the Danish breast cancer cohort, we 131 
also investigated the RBBP8 variants present in the international COMPLEXO 132 
cohort for genome stability after exposure to APH or HU using variant 133 
complementation in CtIP depleted cells. The CtIP-Q643P variant, as well as the 134 
truncating variants CtIP-R185* and CtIP-L372* all displayed increased genome 135 
instability after replication stress (Supplementary table 3). 136 
 137 
CtIP-E804del is proficient in HR repair 138 
To further examine the potential HR repair status of CtIP variants in the Danish 139 
breast cancer cohort, we focussed on the CtIP-E804del variant as it was 140 
significantly enriched in the cohort. We used the tractable U-2-OS cell line, 141 
which is commonly used to evaluate CtIP function (14, 15), and generated an 142 
inducible complementation system expressing siRNA resistant GFP-tagged 143 
full-length CtIP or the CtIP-E804del variant (Supplementary Figure 2C-H). 144 
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Consistent with our previous results in MCF7 cells (Figure 2C), expression of 145 
the CtIP-E804del variant in the U-2-OS cells could rescue the DSB resection 146 
deficiency resulting from CtIP depletion (Supplementary Figure 2C-D). We then 147 
set out to assess HRR efficiency in CtIP-E804del U-2-OS cells, since CtIP-148 
dependent DSB end resection is crucial for efficient HRR. As expected, 149 
expression of CtIP-E804del variant could rescue the HRR deficiency caused 150 
by CtIP depletion (Supplementary Figure 2E-G). Since HRR deficiency can be 151 
therapeutically exploited through the use of PARP inhibitors (PARPi), we also 152 
investigated whether CtIP-E804del variant expression promotes PARPi 153 
sensitivity. As shown in Supplementary Figure 2H using variant 154 
complementation of siRNA depleted cells, CtIP-E804del variant did not display 155 
any increase in PARPi sensitivity over and above Wt-CtIP complemented cells. 156 
Taken together, these results indicate that the CtIP-E804del variant displays 157 
proficient DSB end resection and HRR. Furthermore, this suggests that CtIP 158 
variants deficient in responding to replication stress may promote 159 
tumorigenesis independently of HRR. 160 
 161 
CtIP promotes RAD51 function during replication stress.  162 
In order to functionally characterize a subset of variants in greater detail, the 163 
CtIP-Q643P and CtIP-E804del variants were chosen because they were 164 
significantly enriched in our Danish breast cancer cohort and were associated 165 
with increased genome instability upon HU and APH treatment (Table 2). 166 
Additionally, the CtIP-R805G variant was also chosen due to its close amino 167 
acid sequence proximity to the CtIP-E804del variant and its defective response 168 
to replication stress (Table 2). 169 
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Notably, Q643P, E804del and R805G CtIP variants could not be linked with 170 
deficiency in DNA end resection. As an alternative explanation underlying their 171 
functional contribution, we hypothesized that these variants may instead be 172 
deficient in replication fork degradation which is a recently emerging role for 173 
CtIP (16). To test this hypothesis, we first analyzed the prevalence of RPA foci. 174 
This is a robust marker of ssDNA accumulating at replication forks after HU 175 
treatment, with both increases and decreases in the number of RPA foci per 176 
cell being indicative of replication stress response perturbations. Consistent 177 
with previous reports (17), CtIP depletion led to an increase in HU-induced RPA 178 
foci formation, which could be rescued by expressing exogenous Wt-CtIP-GFP 179 
(Figure 3A-B). Interestingly, this was not the case for both the CtIP-E804del or 180 
CtIP-R805G variants (Figure 3A-B). Serving as negative control, variants that 181 
did not display genomic instability after replication stress could also rescue the 182 
elevated level RPA foci formation resulting from CtIP knockdown 183 
(Supplementary Figure 3A). Intriguingly, the CtIP-Q643P variant suppressed 184 
RPA in a manner comparable to Wt-CtIP (Figure 3A-B). 185 
To obtain insight into the underlying mechanisms, we further examined how 186 
CtIP-depleted cells responded to replication stress. Since RAD51 187 
nucleofilaments protect stalled replication forks from uncontrolled nucleolytic 188 
degradation (5, 18), we addressed whether CtIP affects RAD51 localisation at 189 
damaged forks. As shown in Figure 3C-D, HU-induced RAD51 foci formation 190 
was reduced in MCF7 cells depleted of CtIP. Notably, neither expression of the 191 
E804del nor R805G CtIP variants could complement the loss of HU-induced 192 
RAD51 foci formation caused by CtIP depletion (Figure 3C-D and 193 
Supplementary Figure 3B), whilst this could be restored by transient expression 194 
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of CtIP-Wt and several other CtIP potentially non-pathogenic variants. These 195 
data therefore suggest that the Sae2-like domain of CtIP might play a role in 196 
recruiting/stabilizing RAD51 after replication stress. Intriguingly, the HU-197 
induced RAD51 response was comparable in cells expressing the CtIP-Q643P 198 
variant as to compared to cells expressing Wt-CtIP (Figure 3C-D), which 199 
suggests that this variant promotes replication stress-induced genome 200 
instability via another mode of action. 201 
 202 
In order to directly visualize RAD51 recruitment to the stalled forks after HU 203 
treatment, we turned to isolation of proteins on nascent DNA (iPOND), using 204 
CLiCK chemistry to conjugate biotin to a nucleoside analog (EdU) incorporated 205 
into newly synthesized DNA (19).  Our analyses primarily focused on 206 
comparing Wt-CtIP with the CtIP-E804del variant, since this variant was the 207 
most significantly enriched variant from the Danish cohort that exhibited a 208 
defective response to replication stress. In agreement with our previous data 209 
(Figure 3C-D), using iPOND, the recruitment of RAD51 to nascent DNA 210 
damaged with HU was reduced in the absence of CtIP. Moreover, this 211 
deficiency was restored by the complementation with Wt- CtIP. Importantly, 212 
however, this was not the case after complementation with the CtIP-E804del 213 
mutant (Supplementary Figure 3C). To understand if CtIP is recruited directly 214 
to stalled forks after HU treatment, we employed a proximity ligation assay 215 
(PLA)-based approach that measures the association of proteins on nascent 216 
DNA (20, 21). Following the depletion of CtIP from U-2-OS cells, the expression 217 
of Wt-CtIP or CtIP-E804del was induced in cells with doxycycline. Cells were 218 
then labeled with EdU for 10 min prior to treatment with 4 mM HU for 5 h. Click 219 
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chemistry was then used to conjugate Biotin to EdU and PLA was conducted 220 
to detect protein binding to biotin-labeled nascent DNA. Using this approach, 221 
our data revealed that Wt-CtIP is present at nascent DNA after replication 222 
stress, while CtIP-E804del was absent under the same conditions 223 
(Supplementary Figure 3D-E). 224 
Together, these data suggest that CtIP prevents the accumulation of ssDNA at 225 
damaged replication forks by recruiting/stabilizing RAD51 and that the cancer-226 
associated CtIP variant E804del compromises this function.  227 
 228 
CtIP antagonizes excessive degradation of stalled replication forks 229 
through FBH1. Since RAD51 is known to protect stalled replication forks from 230 
degradation and loss of CtIP is causing a decrease in RAD51 foci formation, 231 
we sought to measure replication fork degradation directly, using the single 232 
molecule DNA fibre-based assay (18, 22). CtIP was depleted from U-2-OS cells 233 
and expression of Wt-CtIP, the E804del or ΔC variants were induced. These 234 
cells were then sequentially pulse-labelled with CldU and IdU to label nascent 235 
DNA before prolonged fork stalling with HU (Figure 4A). In keeping with 236 
previous reports (23), these analyses showed that loss of CtIP results in 237 
increased degradation of nascent DNA at stalled replication forks (Figure 4B). 238 
Moreover, this was abolished upon the expression of Wt-CtIP, but not by 239 
expression of the ΔC mutant (Figure 4C). Importantly, the E804del variant was 240 
partially deficient in replication fork protection after HU (Figure 4C). Thus, we 241 
surmise that the role of CtIP in preventing nascent DNA degradation at stalled 242 
forks involves its C-terminal Sae2-like domain. 243 
 244 
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Finally, we asked whether CtIP plays a role in recruiting RAD51 to stalled forks 245 
in a manner similar to BRCA1/2 or stabilizing RAD51 at these structures like 246 
BOD1L and WRNIP1. Unlike BRCA1/2, BOD1L and WRNIP1 protect damaged 247 
forks by suppressing the anti-recombinase activity of proteins such as FBH1 248 
and BLM (15, 20). Moreover, it has been shown that loss of the anti-249 
recombinase FBH1 increases RAD51 foci formation at stalled replication forks 250 
(24). Therefore, we hypothesized that FBH1 might be involved in evicting 251 
RAD51 from stalled forks in the absence of CtIP. In keeping with this prediction, 252 
concomitant depletion of FBH1 and CtIP rescued RAD51 accummulation in 253 
HU-treated conditions to control levels (Figure 4D-E). To further explore the link 254 
between CtIP and FBH1, we performed fork degradation assays in HU-treated 255 
cells depleted of CtIP, FBH1 or CtIP/FBH1 together (Figure 4F). These 256 
experiments revealed that loss of FBH1 restored nascent DNA stability in the 257 
absence of CtIP (Figure 4F), suggesting that CtIP stabilises RAD51 258 
nucleofilaments to suppress fork degradation. Depletion of FBH1 in cells 259 
expressing the CtIP-E804del variant also restored nascent strand stability, and 260 
re-stabilized RAD51 at stalled replication forks (Figure 4G-H, Supplementary 261 
Figure 4A-B). These data therefore suggest that CtIP regulates replication fork 262 
stability by suppressing FBH1-mediated eviction of RAD51 from stalled forks, 263 
and that cancer-associated mutations in the C-terminus of CtIP perturb this vital 264 
function (Figure 4H). 265 
  266 
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Discussion 267 
Our study demonstrates a role for rare RBBP8 variants in the control of DNA 268 
replication fork integrity. Altogether we identified 13 RBBP8 germline variants 269 
in 21 patients, of which the C-terminal E804del variant was observed in three 270 
patients. Importantly, we identified 3 RBBP8 variants that displayed increased 271 
genome instability. These variants were located in the C-terminus (E804del and 272 
R805G) and LMO4-interacting (Q643P) regions of CtIP. The C-terminus region 273 
is crucial for CtIP functions in genome maintenance and consistent with this, 274 
localization of RAD51 and RPA to sites of damage was impaired by E804del 275 
and R805G variants. Regarding the variant in the LMO4-interacting region 276 
(Q643P), although the functional role for this domain is unclear, it is conceivable 277 
that the breast cancer risk associated with this variant may relate to the 278 
dysregulation of LMO4. However, we were unable to detect a variant-279 
dependent interaction between CtIP and LMO4 (Supplementary Figure 4C). 280 
Additional studies of this variant may identify additional roles for CtIP in 281 
maintaining genome stability and suppressing cancer susceptibility.  282 
 283 
Surprisingly, the subset of CtIP variants promoting genome instability were 284 
functionally wildtype for DNA DSB end resection and HRR. Instead, we 285 
demonstrate that CtIP protects stalled replication forks against enhanced fork 286 
degradation by promoting RAD51 nucleofilament stability, and it is this function 287 
that is perturbed by variants associated with early-onset breast cancer. Thus, 288 
these results suggest that CtIP insufficiency may predispose to breast cancer 289 
by allowing deleterious replication fork degradation (Figure 4I). Interestingly, 290 
loss of fork protection is a potential target for cancer therapy, since the ability 291 
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of BRCA1/2-deficient cells to acquire drug resistance is intimately linked to fork 292 
protection (6). 293 
 294 
A pathway protecting stalling DNA forks from degradation was first uncovered 295 
in cells with BRCA2 insufficiency, and more recently has been reported in cells 296 
lacking critical tumor suppressors known to be involved in regulating HRR, 297 
including BRCA1, PALB2, and FANCD2 (6, 18, 21, 25). Our research now links 298 
CtIP with these factors that allow stable RAD51 accummulation when forks are 299 
challenged. However, unlike BRCA1, BRCA2 and PALB2, we suggest that CtIP 300 
belongs to a family of replication fork protection factors, including BOD1L and 301 
WRNIP1, that regulate the FBH1 helicase, a RAD51-evicting factor. Thus, in 302 
the absence of RAD51-stabilising factors, FBH1 reduces the presence of 303 
RAD51 at stalled forks, allowing uncontrolled fork degradation that can trigger 304 
genome instability. This is an emerging biological response to fork stalling, and 305 
the links with tumorigenesis are only now starting to be dissected. Notably, our 306 
functional findings on CtIP are in agreement with recently published data that 307 
also identify a role for CtIP in suppressing degradation of stalled replication 308 
forks (16). The authors focused on the role of the N-terminal region of CtIP that 309 
helps to minimize nucleolytic degradation by the DNA2 nuclease. Thus far, we 310 
have not identified cancer-associated disabling variants in this CtIP region. 311 
 312 
The roles of CtIP in breast cancer predisposition and progression are not well 313 
understood, though studies have indicated that a lack or low levels of CtIP 314 
expression in tumor cells is associated with a reduced survival rate (23, 26). 315 
Furthermore, tumors lacking CtIP display an impaired ability to repair DSB, 316 
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which leads to increased sensitivity to PARP inhibitors (26, 27). Thus, 317 
determining the impact of identified variants in CtIP on its function should be 318 
considered when trying to personalise a therapeutic approach for treating a 319 
specific patient. Intriguingly, analysis of a cohort of 129 BRCA1 and BRCA2 320 
mutation-negative Australian breast cancer patients failed to demonstrate an 321 
enrichment of coding variants in RBBP8 (28). In fact, no coding RBBP8 variants 322 
were identified except for a polymorphism in intron 6. In contrast, a recent 323 
Spanish study identified two truncating RBBP8 variants in two early-onset 324 
BRCA1/2 mutation negative BC patients (29). Furthermore, we identified two 325 
functionally damaging truncating variants in the COMPLEXO cohort in addition 326 
to the Q643P variant also described here. The differences between studies may 327 
reflect population differences, cohort sizes as well as age of BC onset in the 328 
cohorts. 329 
 330 
Murine studies have indicated that CtIP haploinsufficiency is tumor promoting, 331 
whereas a complete loss of CtIP is detrimental leading to inviability of mice (30). 332 
In contrast, murine tissue-specific conditional CtIP ablation systems indicated 333 
that a complete loss of CtIP supresses tumorigenesis (31). However, it is likely 334 
that these observations are due to a deleterious decrease in cellular fitness 335 
linked to a complete loss of HRR. Importantly, we have shown that a subset of 336 
RBBP8 variants identified in this study are hypomorphic in a manner where 337 
they impair some functions of CtIP but not all. Based on this, we propose that 338 
hypomorphic but not loss-of-function mutations in RBBP8 predispose to early-339 
onset breast cancer. We cannot exclude the possibility that these variants may 340 
represent rare variants with little association with cancer development. 341 
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However, it is noteworthy that we identified RBBP8 germline variants in early-342 
onset breast cancer patients at a frequency similar to that previously reported 343 
for HBOC-associated mutations in BRIP1, RECQL1 and PALB2 (3, 8-10). 344 
Thus, since our data indicates that RBBP8 variants are more frequent in early-345 
onset breast cancer cases than in unaffected population-matched controls, this 346 
warrants consideration of RBBP8 being included in the gene panel when 347 
carrying out breast cancer predisposing sequencing studies. Finally, our study 348 
shows the usefulness of combining genetic screening in a high-risk phenotype 349 
with comprehensive variant-centered functional analysis to identify and classify 350 
new variants implicated in hereditary cancer syndromes. 351 
  352 
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Experimental procedures 353 
Patients 354 
All patient samples were consecutively recieved for HBOC diagnostics over a 355 
period of 20 years, according to the contempary national HBOC guidelines 356 
(Danish Breast Cancer Cooperative Group (DBCG)). Clinical and 357 
histopathological data were retrieved from the Danish Pathology Registry and 358 
the DBCG registry. Patients were diagnosed between year 1978 to 2016.  359 
 360 
Patient group I included 129 breast and/or ovarian cancer patients, previously 361 
identified as BRCA1/2 pathogenic-variant-negative as part of their diagnostic 362 
work-up (124 females and 5 males). Female patients diagnosed with ovarian 363 
or with breast cancer at the age of 35 years or younger, while male breast 364 
cancer patients were included regardless of age at time of diagnosis. Among 365 
the female patients, 116 had breast cancer only, six had ovarian cancer only, 366 
one had breast and ovarian cancer, and one had breast and cervical cancer. 367 
Four of the men had breast cancer only, whereas 1 had both breast and 368 
prostate cancer. Mean age at time of diagnosis of the female patients was 30 369 
years and for male 59 years.  370 
 371 
Patient group II included 1,092 BRCA1/2 - negative samples from unselected 372 
and consecutive patients undergoing genetic screening for HBOC according to 373 
clinical guidelines as described above.   374 
 375 
Sequencing of RBBP8  in patient group I  376 
 18 
Genomic DNA was purified from peripheral blood samples and library 377 
preparation was performed using SeqCap EZ Human Exome Library v3 (Roche 378 
NimbleGen, Madison, WI, USA) or SureSelect All Exon kit v5 (Agilent 379 
Technologies, Santa Clara, CA, USA) following manufactures’ instructions.  380 
Sequencing was conducted using the HiSeq2500 or NextSeq500 platforms 381 
from Illumina (San Diego, Ca, USA). The average coverage of all exomes was 382 
65x.  383 
 384 
Data processing 385 
Fastq files were processed using CLC Biomedical Genomics Workbench v3 386 
(Qiagen, Hilden, Germany). Reads were mapped to the human reference 387 
genome hg19/GRCh37 and variant calling was performed by a Maximum 388 
Likelihood approach on a Baysian model. Variants were called with a minimum 389 
of 10 reads, 3 counts and a frequency of >25 %. Called variants were filtered 390 
using Ingenuity Variant Analysis (http://ingenuity.com). First, variants with call 391 
quality <20 and read depth <10; were disregarded. Second, variants with an 392 
allele frequency >1% of the public variant database including 1000 genomes 393 
project (www.1000genomes.org), ExAC (http://exac.broadinstitute.org) or 394 
gnomAD (http://gnomad.broadinstitute.org), or unless established as a 395 
pathogenic common variant, were excluded. Third, only coding non-396 
synonymous variants and splice-site variants (+/-2bp) were kept. Finally, output 397 
was filtered to include the RBBP8 gene. Samples (n=1054) from the 398 
COMPLEXO consortium were initially processed from raw fastq reads and  399 
aligned to the human genome reference (hg19) using bwa (v0.5.9) on a per 400 
lane basis. Alignment file pre-processing and germline variant calling was 401 
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performed by The Genome Analysis Toolkit (GATK) v3.1 (v3.1-144). 402 
HaplotypeCaller algorithm was used to generate variant files (.vcf) which  were  403 
filtered to include only rare variants in the RBBP8 gene (<1% in ExAC). 404 
 405 
Sequencing of RBBP8  in Patient group II 406 
Screening of the larger group for RBBP8 variants was performed using a gene 407 
panel. The library was designed to capture all exons as well as the first and last 408 
50 bp of the intronic regions. Samples were pooled into groups of four and 409 
deeply sequenced (average coverage of 5.500x). Mapping and variant calling 410 
was done as described for patient group I, however as samples were pooled 411 
into groups of four, variants were called with a minimum of 100 reads, 10 counts 412 
and frequency of 6.25 % (corresponding to a variant detection rate of 25 % pr. 413 
sample). Variant filtering was performed using Ingenuity Variant Analysis.  414 
 415 
Sanger sequencing 416 
All non-polymorphic RBBP8 variants identified by sequencing of the two patient 417 
groups were verified by PCR and Sanger sequencing (for primer sequences 418 
see Supplemental table 4).  419 
 420 
Statistical Analysis of allelic association with Breast Cancer 421 
Fisher’s exact test was employed to determine if identified RBBP8 variants 422 
were enriched in the examined breast cancer patient cohorts compared to the 423 
2,000 Danes were used as controls in the statistical analysis.  424 
 425 
Cell culture  426 
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The human cancer cell lines were cultured for 5 days at 37°C and 5% CO2 as 427 
follows: The human breast cancer cells (MCF7) were cultured in RPMI (GIBCO, 428 
Life Technologies), supplemented with 10% FBS (Sigma Aldrich), and 1% 429 
penicillin/streptomycin (GIBCO, Life Technologies). The human osteosarcoma 430 
cell line (U-2-OS), harboring inducible GFP-tagged siRNA resistant CtIP were 431 
grown in Dulbecco's modified Eagle's medium with 10% tetracycline-free FBS 432 
(Clontech) 1% penicillin/streptomycin (GIBCO, Life Technologies), 100 ug/ml 433 
Zeocin (Invitrogen) and 5 ug/ml Blasticidin (Invitrogen). The human embryonic 434 
kidney 293FT cells were grown in Dulbecco's modified Eagle's medium with 435 
10% FBS (Sigma Aldrich) and 1% penicillin/streptomycin (GIBCO, Life 436 
Technologies).  437 
 438 
Lentiviral infection 439 
The doxycycline inducible stable U-2-OS cell lines expressing the pcDNA4/TO 440 
tagged siRNA‐resistant versions of wild‐type and mutant CtIP were established 441 
by cloning CtIP cDNA into pcDNA4/TO‐GFP vector (Invitrogen). The ΔC 442 
truncation of CtIP is lacking amino acids 790–897. 443 
The GFP-CtIP plasmids were sub-cloned into pLVX-TetOne Vector (Clontech) 444 
and were co-transfected with Pax8 (Clontech) and VSVG (Clontech) into 445 
HEK293 FT cells using FugeneHD (Promega). The generated CtIP lentivirus 446 
were then transduced into U-2-OS using polybrene according to the 447 
manufacturer's protocol resulting in cell lines expressing GFP- tagged siRNA‐448 
resistant CtIP Wt, E804del, or ΔC in a Tet-on system. To induce expression of 449 
siRNA resistant CtIP, doxycycline (1 ng/ml) was added to the medium for 450 
approximately 24 h.  451 
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 452 
Site directed mutagenesis 453 
The mutant CtIP plasmids were generated by site‐directed mutagenesis of the 454 
siRNA‐resistant Wt-CtIP. The following primers were used: 455 
CtIP R100W: Fw: 5'-ACTGAAGAACATATGTGGAAAAAACAGCAAG 456 
CtIP R100W: Re: 5'-CTTGCTGTTTTTTCCACATATGTTCTTCAGT 457 
CtIP R110Q: Fw: 5'-GAGTTTGAAAATATCCAGCAGCAGAATCTTAAA 458 
CtIP R110Q: Re: 5'-TTTAAGATTCTGCTGCTGGATATTTTCAAACTC 459 
CtIP R185*: Fw: 5’-AGAACCCCCATGTCTGATACATAGAACAAA 460 
CtIP R185*: Re: 5’-TTTGTTCTATGTATCAGACATGGGGGTTCT 461 
CtIP V198M: Fw: 5’-AAATTGGAGCACTCTATGTGTGCAAATGAAAT 462 
CtIP V198M: Re: 5’-ATTTCATTTGCACACATAGAGTGCTCCAATTT 463 
CtIP S231R: Fw: 5'- CACTTATGACCAAAGACAATCTCCAATGGCC 464 
CtIP S231R: Rev: 5'- GGCCATTGGAGATTGTCTTTGGTCATAAGTG 465 
CtIP E267G: Fw: 5’-ACTTGGTGTTCAAGGAGAATCTGAAACTC 466 
CtIP E267G: Re: 5’-GAGTTTCAGATTCTCCTTGAACACCAAGT 467 
CtIP Q272E: Fw: 5’-AAGAATCTGAAACTGAAGGTCCCATGAG 468 
CtIP Q272E: Re: 5’-CTCATGGGACCTTCAGTTTCAGATTCTT 469 
CtIP G331A: Fw: 5’-ATCTCCTGTATTTGCAGCTACCTCTAGTA 470 
CtIP G331A: Re: 5’-TACTAGAGGTAGCTGCAAATACAGGAGAT 471 
CtIP Q352P: Fw: 5’-CCTTCTCTTTTACCGCCTGGGAAAAAAA 472 
CtIP Q352P: Re: 5’-TTTTTTTCCCAGGCGGTAAAAGAGAAGG 473 
CtIP I369V: Fw: 5’-CTTTTAGCAACACTTGTGTATCTAGATTAGAAAA 474 
CtIP I369V: Re: 5’-TTTTCTAATCTAGATACACAAGTGTTGCTAAAAG 475 
CtIP L372*: Fw: 5’-CACTTGTATATCTAGATGAGAAAAAACTAGATCA 476 
 22 
CtIP L372*: Re: 5’-TGATCTAGTTTTTTCTCATCTAGATATACAAGTG 477 
CtIP E414D: Fw: 5’-AATAAAAATATAAGTGATTCCCTAGGTGAACAGA 478 
CtIP E414D: Re: 5’-TCTGTTCACCTAGGGAATCACTTATATTTTTATT 479 
CtIP H456R: Fw: 5'-GAGGAAGAAAGTGAACGTGAAGTAAGCTGC 480 
CtIP H456R: Re: 5'-GCAGCTTACTTCACGTTCACTTTCCTC 481 
CtIP R502L: Fw: 5'-TTTTCAGCTATTCAGCTTCAAGAGAAAAGCCAA 482 
CtIP R502L: Re: 5'-TTGGCTTTTCTCTTGAAGCTGAATAGCTGAAAA 483 
CtIP E552D: Fw: 5’-ATTCCCCAGGGGATCCCTGTTCACA 484 
CtIP E552D: Re: 5’-TGTGAACAGGGATCCCCTGGGGAAT 485 
CtIP R589H: Fw: 5'-TTTAAAATTCCTCTACATCCACGTGAAAGTTTG 486 
CtIP R589H: Re: 5'-CAAACTTTCACGTGGATGTAGAGGAATTTTAAA 487 
CtIP Q643P: Fw: 5'-AAAATAAAGTCTCTACCAAACAACCAAGATGTA 488 
CtIP Q643P: Re: 5'-TACATCTTGGTTGTTTGGTAGAGACTTTATTTT 489 
CtIP E711K : Fw: 5'-CAAGAGCAGAAGGGAAAAAAAAGTTCAAATG 490 
CtIP E711K : Re: 5'-CATTTGAACTTTTTTTTCCCTTCTGCTCTTG 491 
CtIP E716K: Fw: 5’-GGGAGAAAAAAGTTCAAATAAAGAAAGAAAAATGAA 492 
TG 493 
CtIP E716K: Re: 5’-CATTCATTTTTCTTTCTTTATTTGAACTTTTTTCTCCC 494 
CtIP E804del: Fw: 5'-GTGGTTCGGAAAAAAGAGAGAAGA…CAG 495 
CtIP E804del : Re: 5'-GTGTGCCCAAGCAGTTTTCTTCTC…CAC 496 
CtIP R805: Fw: 5'-GTTCGGAAAAAAGAGGAGGGAAGAAAACTGCTTGGGC 497 
CtIP R805G : Re: 5'-GCCCAAGCAGTTTTCTTCCCTCTTTTTTCCGAA 498 
CtIP R839G : Fw: 5'-GGAATGTAGCGGAATCCGTGTCTTGAGCAGGAA 499 
CtIP R839G : Re: 5'-TTCCTGCTCAAGACACGGATTCCGCTACATTCC 500 
CtIP P847A : Fw: 5'- AAGGAAGATCTTGATGCTTGTCCTCGTCCAA 501 
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CtIP P847A : Re: 5'- TTGGACGAGGACAAGCATCAAGATCTTCCTT 502 
CtIP R877H: Fw: 5’-TTGATCCTTGTCCTCATCCAAAAAGACGT 503 
CtIp R877H: Re: 5’-ACGTCTTTTTGGATGAGGACAAGGATCAA 504 
CtIP E894D : Fw: 5'- TCCAAAAGGCAAGGACCAGAAGACATAGACG 505 
CtIP E894D : Re: 5'- CGTCTATGTCTTCTGGTCCTTGCCTTTTGGA 506 
CtIP ΔC: Fw: 5'-GAAAGAGAGACTAGCTAGCAAAATTTTCCTCAT 507 
CtIP ΔC: Re: 5'-ATGAGGAAAATTTTGCTAGCTAGTCTCTCTTTC 508 
The PFU ultra‐high‐fidelity polymerase (Agilent) was used according to the 509 
manufacturer's protocol. 510 
 511 
Oligonucleotides and transfection 512 
For siRNA transfections (48 h), Lipofectamine RNAiMAX (Invitrogen) was used 513 
according to the manufacturer's protocol. MISSION® siRNA universal negative 514 
control (UNC, Sigma) was used as a negative control, and the oligonucleotide 515 
sequences used for knockdown of CtIP was 5'-GCUAAAACAGGAACGAAU 516 
which was obtained from Microsynth  (Balgach,Switzerland), for depleting 517 
FBH1, a mix of two sequences 5′‐GGGAUGUUCUUUUGAUAAA and 5′‐518 
CCAUCCAACUUACACAUGA was used. 519 
 520 
Reagents 521 
Hydroxyurea (Sigma aldrich) was used at a final concentration of 4 mM for the 522 
indicated time. Aphidicolin (Sigma aldrich) was used at a final concentration of 523 
0.3 μM for the indicated time. Furthermore, Cytochalasin B (Sigma aldrich) was 524 
used at a concentration of 1 μg/ml. 525 
 526 
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Western blotting and antibodies 527 
Cells were lysed on ice in EBC buffer (50 mM Tris, pH 7.4, 120 mM NaCl, 0.5% 528 
NP-40, and 1 mM EDTA) containing protease inhibitors (1% vol/vol aprotinin, 5 529 
g/ml leupeptin, 1 mM PMSF), phosphatase inhibitors (1 mM NaF, 10 mM -530 
glycerophosphate), and 1 mM DTT. The lysates were sonicated, using a digital 531 
sonifier (102C CE Converter; Branson), followed by centrifugation at 20,000xg 532 
for 15 min. Proteins were resolved by SDS-PAGE and transferred to 533 
nitrocellulose membrane. The membrane were incubated with primary antibody 534 
followed by incubation with secondary antibody (HRP-conjugated anti-mouse 535 
or -rabbit IgG; Vector Laboratories). Immunoblots were performed using the 536 
following antibodies: CtIP (#A300488A, Bethyl Laboratories), RAD51 (#8349, 537 
Santa Cruz), RAD51 (#63801, Abcam), PCNA (#18197, Abcam), FBH1 538 
(FBXO18, #81563, Santa Cruz), GFP (#1181446000, Roche), Actin (#AB1501; 539 
Millipore), RPA2 S4/8 (#A300245A, Biosite), RPA (#NA29L, Millipore), Vinculin 540 
(#V9131, Sigma), BRCA2 (#OP95, Calbiochem), H3 (#1791, Abcam), HA 541 
(#MMS-101P-500, Covance). 542 
 543 
Immunofluorescence 544 
The cells were grown on coverslips and treated as indicated and then prepared 545 
for immunofluorescence staining. Primary antibodies used were RAD51 546 
(1:1,000, 70‐001, BioAcademia Jpn), GFP (1:1,000, #1181446000, Roche), 547 
RPA (#NA29L, Millipore), RPA2 S4/8 (#A300245A, Biosite). Anti‐rabbit Alexa 548 
Fluor 647, anti‐mouse Alexa Fluor 488 (1:2,000, A21245, A11017, Life 549 
Technologies) were used as secondary antibodies. For RAD51, 550 
immunofluorescence cells were pre‐extracted twice for 3 min in CSK buffer 551 
 25 
(0.5% Triton X‐100, 20 mM Hepes pH 7.4, 100 mM NaCl, 3 mM MgCl2, and 552 
300 mM sucrose) followed by fixation in 4% paraformaldehyde (PFA) (VWR). 553 
Cells were permeablized in 0.5% Triton X‐100 followed by incubation in 554 
blocking buffer (1% BSA, 0.15% glycine, 0.1% Triton X‐100 in PBS wash buffer 555 
(1× PBS, 0.1% Tween‐20, 1 mM CaCl2, 0.5 mM MgCl2). Primary antibody was 556 
incubated for 1 h at room temperature in blocking buffer, followed by three 557 
washes with PBS wash buffer. Secondary antibody was incubated for an 558 
additional hour, washed 3x with PBS wash buffer, and mounted in mounting 559 
vectashield with diamidino-2-phenylindole (DAPI) (vector Laboratories). EdU 560 
staining was done per manufacturer's instructions (Life Technologies). Z‐stack 561 
images were acquired on a confocal Zeiss LSM 510 meta microscope 562 
workstation, and images were processed and foci enumerated using Fiji 563 
(ImageJ).  564 
 565 
Micronuclei assay 566 
Cells were cultured on coverslips post-transfection and were incubated for 567 
another 24 h before starting the treatment of the cells. Cells were treated with 568 
Aphidicolin (Sigma aldrich) for 16 h or Hydroxyurea (Sigma Aldrich) for 5 h. In 569 
addition, cells were treated with Cytochalasin B (Sigma Aldrich) for 36 h   570 
(MCF7), to inhibit cytokinesis, and then fixed in 4% paraformaldehyde (PFA) 571 
(VWR). Next, the cells were permeabilized with 0.25% Triton X-100 solution, 572 
washed twice with 1xPBS and mounted in Vectashield with diamidino-2-573 
phenylindole (DAPI) (vector Laboratories), binucleated cells with a micronuclei 574 
was counted manually using a confocal Zeiss LSM 510 meta microscope and 575 
a Scan^R workstation (Olympus).  576 
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 577 
HR assay  578 
U-2-OS cells transfected with CtIP siRNA followed by transfection of gRNAs 579 
targeting the LMNA locus and the Ruby Donor plasmid as described in 580 
reference (32) together with empty vector or siRNA-resistant Wt, E804del or 581 
ΔC CtIP. After 48 h, Lamin A (LMNA) genes were monitored by microscopy.  582 
 583 
iPond 584 
DOX‐inducible U-2-OS cells were transfected with both UNC (negative control) 585 
or CtIP siRNA and 24 h later, cells were induced with DOX for 24 h. Cells were 586 
incubated with 10 μM EdU for 15 min, washed in media, then incubated with 587 
media containing 4 mM HU for 5 h, cross-linked with 1% formaldehyde, 588 
harvested and permeabilised. Biotin azide was covalently attached to EdU 589 
within newly replicated DNA using a Click reaction, and EdU containing DNA 590 
was precipitated using Streptavidin agarose beads. Eluted proteins were then 591 
analysed by SDS-PAGE and WB. 592 
 593 
DNA fibres 594 
DNA fibres were carried out as described previously (22). Twenty-four hours 595 
post siRNA transfection cells were treated with doxycycline to induce CtIP 596 
expression, and left for a further 24 h. Cells were then pulse-labelled with CldU 597 
and IdU for 20 min each before a 5 h exposure to 4 mM HU. At least 200 598 
replication forks were analysed per condition. Tract lengths were measured 599 
using Fiji, and ratios calculated. 600 
 601 
 27 
Proximity ligation assay on nascent DNA  602 
Twenty-four hours post siRNA transfection cells were treated with doxycycline 603 
to induce CtIP expression, and left for a further 24 h. Cells were then pulse-604 
labelled with 10 mM EdU for 10 min followed by 4 mM HU for 5 hr. After the 605 
indicated treatment, cells were pre‐extracted for 5 min in buffer (0.5% Triton X‐606 
100, 10 mM PIPES pH 6.8, 20 mM NaCl, 3 mM MgCl2, and 300 mM sucrose) 607 
followed by fixation in 4% paraformaldehyde (PFA) (VWR). Cells were 608 
incubated in blocking buffer (3% BSA, in PBS with 0.1% Na Azide for 1hr room 609 
temperature or O/N in the cold room). After blocking, cells were subjected to 610 
Click reaction with biotin-azide for 30 min and incubated overnight with the two 611 
relevant primary antibodies at 4°C. The primary antibodied were diluted in PBS 612 
with 3% FCS. The primary antibodies used were rabbit polyclonal anti-biotin 613 
(1:500, #A150-109A,  Bethyl), mouse monoclonal anti-biotin (1:500, #200-002-614 
211, Jackson immunoresearch), rabbit polyclonal anti-CtIP (1:500, # A300-615 
266A, Bethyl). The PLA reaction (Duolink, Sigma Aldrich) to detect anti-biotin 616 
antibodies used were performed according to manufacturer instructions. 617 
 618 
Immunoprecipitation  619 
Extracts for immunoprecipitation were prepared using immunoprecipitation 620 
buffer (50 mM Hepes, pH 7.5, 150 mM NaCl, 1 mMEDTA, 2.5 mM EGTA, 10% 621 
glycerol, 0.1% Tween) with protease inhibitors. Following preclearing with IgG-622 
coupled protein G beads (GE Healthcare), the lysates were incubated with 623 
monoclonal anti-HA (Covance), and complexes were captured using Protein G 624 
Sepharose beads (GE Healthcare) for at 4°C on a rotator. The beads were 625 
washed five times followed by elution of bound proteins in Laemmli sample 626 
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buffer. 627 
 628 
PARPi sensitivity Assay 629 
DOX‐inducible U-2-OS cells were seeded on to the CellCarrier-384 Ultra 630 
Microplates (PerkinElmer, Massachusetts, United States) and reverse 631 
transfection was performed using Lipofectamine RNAiMAX as per the 632 
manufacturer’s recommendation. After 24 h, DMSO and different 633 
concentrations of Talazoparib (BMN 673, Axon Medchem, the Netherlands) 634 
were added to the respective wells. On day 3, DMSO and PARPi containing 635 
media were replenished. At day 5, CellTiter-Glo (Promega, Wisconsin, United 636 
States) was used to quantify the number of viable cells as per the 637 
manufacturer’s recommendation. Surviving fractions were calculated relative to 638 
DMSO-exposed cells for each PARPi concentration.  639 
 640 
Statistics 641 
Normal distribution was assessed for all experiment. Micronuclei data was 642 
normally distributed and subsequently analyzed using a One-way ANOVA and 643 
Dunnett’s multiple comparison testing, comparing all variants to Wt-CtIP-GFP. 644 
The PARP inhibitor data (Supplementary Figure 2i) were Johnson transformed 645 
and the obtained, normally distributed data were fitted with a linear mixed 646 
model, with replicates as random effect. Multiple comparisons were performed 647 
with the lsmeans/difflsmeans and the contrast function of the lmer package in 648 
R. Significant codes shown are comparing siCtIP and siBRCA2 to the negative 649 
control (siUNC). Foci counts, immunofluorescence intensities as well as HRR 650 
data were not normally distributed. Therefore, ranks were assigned to all data 651 
 29 
from three biologically independent replicates, based on the number of foci/ 652 
immunofluorescence intensity. The obtained ranks were used to fit a linear 653 
mixed model. P values were adjusted using the holm method if more than two 654 
comparisons were made. Biologically relevant p values are reported with the 655 
following significant codes: p <0.0001  ‘***’; p <0.001 ‘**’; p <0.05 ‘*’. All graphs 656 
represent the mean (red line) ± SEM (black). 657 
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Tables 849 
Table 1. Identified RBBP8 variants and allele frequencies. AF = Allele 850 
Frequency; Fisher Exact Test for AF in Group I and Group I + II compared to 851 
AF in controls (2.000 Danish individuals (Lohmueller et al., 2013)). Non-Finnish 852 
European (NFE) in gnomAD. 853 
 854 
 855 
 856 
 857 
 858 
 859 
 860 
 861 
 862 
 863 
 864 
  865 
Nucleotide 
(HGVS) 
Protein 
(HGVS) 
Exon Group 
I 
Group 
II 
AF 
Group 
I (%) 
AF 
Group 
I + II 
(%) 
AF 
controls 
(%) 
AF 
NFE 
(%) 
p-value 
AF 
(Group I 
vs 
controls) 
p-value 
AF 
(Group I 
+ II vs 
controls) 
c.298C>T p.R100W 6 1  0.388 0.041 0.025 0.008 ns ns 
c.329G>A p.R110Q 6  3 - 0.123 0.153 0.070 - ns 
c.693T>A p.S231R 9 1  0.388 0.041 - - ns ns 
c.1367A>G p.H456R 12  2 - 0.082 0.127 0.220 - ns 
c.1505G>T p.R502L 12  1 - 0.041 0.025 0.003 - ns 
c.1928A>C p.Q643P 13 1 3 0.388 0.164 - 0.014 ns 0.02 
c.2024C>T p.T675I 14  1 - 0.041 - 0.011 - ns 
c.2131G>A p.E711K 15 1  0.388 0.041 - - ns ns 
c.2410_2412del p.E804del 18 3  1.163 0.123 - 0.015 0.0002 ns 
c.2413A>G p.R805G 18  1 - 0.041 - 0.003 - ns 
c.2516G>A p.R839Q 19  1 - 0.041 - 0.088 - ns 
c.2620C>G p.P874A 20  1 - 0.041 - 0.008 - ns 
c.2682G>C p.E894D 20  1 - 0.041 - - - ns 
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Table 2. CtIP suppresses genomic instability at perturbed replication forks. 866 
MCF7 cells transfected with the indicated siRNA followed by transfection of Wt 867 
or its mutated CtIP variants. Further, cells were treated with IR or the indicated 868 
dose of APH for 16 h or 4mM HU for 5h and Cytochalasin B for 36 h. DAPI stain 869 
was used to visualize nuclei. Cells were imaged with a 20x objective on a 870 
Scan^R workstation (Olympus). At least 100 green cells were counted for each 871 
genotype per experiment. One-Way ANOVA with Dunnett’s multiple 872 
comparison test was performed on three independent replicates. All variants 873 
were compared to Wt-CtIP-GFP. 874 
 875 
 876 
 877 
 878 
 879 
 880 
 881 
 882 
 883 
 884 
 885 
  Cytochalasin B IR   APH HU 
CtIP 
variants 
% of 
binuclei 
with 
micronuclei 
p 
value 
% of 
binuclei 
with 
micronuclei p value 
% of 
binuclei 
with 
micronuclei p value 
% of 
binuclei 
with 
micronuclei p value 
Vector 
(GFP) 49.95   67.30   66.67   67.14   
Wt 47.37 - 46.46 - 47.96 - 48.36 - 
R1100W 45.13 Ns 48.38 ns 47.53 Ns 47.39 ns 
R110Q 46.46 Ns 47.99 ns 49.31 Ns 50.18 ns 
S231R 47.09 Ns 48.29 ns 49.29 Ns 47.36 ns 
H456R 47.76 Ns 49.76 ns 47.99 Ns 45.34 ns 
R502L 48.77 Ns 49.43 ns 50.12 Ns 50.14 ns 
R589H 48.99 Ns 48.04 ns 48.77 Ns 47.70 ns 
Q643P 49.33 Ns 48.45 ns 60.74 **** (0.0001) 57.83 ** (0.0030) 
E711K 46.35 Ns 48.03 ns 45.47 Ns 48.20 ns 
E804del 49.34 Ns 47.99 ns 65.32 **** (0.0001) 69.32 **** (0.0001) 
R805G 51.62 Ns 48.94 ns 66.67 **** (0.0001) 68.15 **** (0.0001) 
R839Q 49.79 Ns 47.60 ns 49.12 Ns 48.28 ns 
P874A 48.72 Ns 48.89 ns 50.20 Ns 48.53 ns 
E894D 47.46 Ns 47.39 ns 49.09 Ns 49.17 ns 
delta C 50.37 Ns 61.26 **** (0.0001) 59.38 *** (0.0002) 58.78 *** (0.0010) 
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Figure 1. Identification of RBBP8 germline variants. (A) Schematic representation of the 
identified variants at gene level indicated according to exon location. (B) Schematic 
representation of the identified variants at protein level indicated according to known 
functional domains. The multimerization domain (aa 45-165), the Sae2-like domain (aa 790-
897) and the BRCA1 binding site are indicated. All variants further investigated in the 
functional studies are indicated in bold. 
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Figure 2. Subset of RBBP8/CtIP variants display a genome maintenance defect. (A-B) 
Western blot analysis of CtIP siRNA, GFP CtIP variants, Actin and Vinculin expression in 
MCF7 cells. Actin and Vinculin were used as loading controls. (C) The relative intensity of 
phosphorylated RPA (S4/8) was examined in the total population of Wt or its mutated CtIP 
variants 3 h post exposure to IR (15 Gy). Cells were fixed and stained for pRPA (S4/8). Each 
of the variants was compared to Wt-CtIP-GFP, but no significant changes were observed. 
The displayed data represents three independent biological replicates and per sample 
n≥280 nuclei were analyzed. Holm-corrected multiple testing was performed of ranked data 
fitted by a linear mixed model, comparing all CtIP variants to Wt-CtIP-GFP. 
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Figure 3: CtIP prevents ssDNA accumulation after replication stress. (A) Representative 
images displaying RPA in HU-treated EdU-positive cells. Scale bar= 20 μm. (B) MCF7 cells 
were transfected with the indicated siRNA and 24 h later, cells were transfected with Wt or 
its mutated CtIP variants. Afterwards cells were pulsed with 10 μM EdU for 20 min prior to 
addition of 4 mM HU. Cells in S phase (EdU+) at the time of HU treatment were Click-IT 
labeled with an Alexa Fluor 594 azide and RPA intensity in EdU-positive cells were 
enumerated using Image J/Fiji. The displayed data represents three independent biological 
replicates and per sample n≥174 nuclei were analyzed. Holm-corrected multiple testing was 
performed of ranked data fitted by a linear mixed model, comparing all CtIP variants to Wt-
CtIP-GFP. (C) Representative images displaying RAD51 in HU-treated EdU-positive cells. 
Scale bar= 20 μm. (D) MCF7 cells were transfected with the indicated siRNA and 24 h later, 
cells were transfected with Wt or mutated CtIP variants. Afterwards cells were pulsed with 
10 μM EdU for 20 min prior to addition of 4 mM HU. Cells in S phase (EdU+) at the time of 
HU treatment were Click-IT labeled with an Alexa Fluor 594 azide and RAD51 foci in EdU-
positive cells were enumerated using Image J/Fiji.  The displayed data represent three 
independent biological replicates and per sample n≥207 nuclei were analyzed. Holm-
corrected multiple testing was performed of ranked data fitted by a linear mixed model, 
comparing all CtIP variants to Wt-CtIP-GFP. 
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Figure 4: CtIP promotes replication fork protection through FBH1. (A) Experimental scheme 
of dual labeling of DNA fibres in DOX inducible U-2-OS cells stably expressing the siRNA 
resistant full-length Wt, E804del or ΔC CtIP. Cells were sequentially pulse-labeled with CldU 
and IdU, then treated with 4 mM HU for 5 h. (B-C) Loss of CtIP results in replication fork 
instability in response to replication stress. DOX-inducible U-2-OS cells were transfected 
with either UNC (negative control) or CtIP siRNA and 24 h later, cells were induced with 
DOX for 24 h. IdU:CldU ratios are given. (D-E) Representative images displaying RAD51 in 
HU-treated EdU-psoitive cells, scale bar= 20 μm. MCF7 cells were transfected with the 
indicated siRNAs. Cells were pulsed with 10 μM EdU for 20 min prior to addition of 4 mM 
HU. Cells in S phase (EdU+) at the time of HU treatment were Click-IT labeled with an Alexa 
Fluor 594 azide and RAD51 foci in EdU-positive cells were enumerated using Image J/Fiji. 
The displayed data represents three independent biological replicates and per sample 
n=224 nuclei were analyzed. Holm-corrected multiple testing was performed of ranked data 
fitted by a linear mixed model. (F) U-2-OS cells were transfected with the indicated siRNAs 
and exposed to 4 mM HU for 5 h. IdU:CldU ratios are given. (G) U-2-OS cells were 
transfected with the indicated siRNAs and exposed to 4 mM HU for 5 h. IdU:CldU ratios are 
given. (H) U-2-OS cells were transfected with the indicated siRNAs and exposed to 4 mM 
HU for 5 h. IdU:CldU ratios are given. (I) Schematic model for the role of CtIP at stalled 
forks. CtIP regulates RAD51 stability at stalled forks, counteracting the dissolution of the 
RAD51 filament by FBH1. Loss of CtIP leads to DNA damage accumulation and enhanced 
chromosomal instability. 
 
